Levitz L - EpiVax, Inc. - Informatics and Immunology

Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes

Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2012 Jul;8(7):987-1000.

Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine

Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine

by epivax3 | Oct 22, 2016

Vaccine. 2012 Dec 14;30(52):7547-60. PMCID: PMC3522424

Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Jul;9(7):1555-7. doi: 10.4161/hv.24833. Epub 2013 May 31.

Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. Volume 9, Issue 5 May 2013:950–956.

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Sep 17;9(10).